Arca
Skip to content
Tools
Tools

F: Fusion glycoprotein F0

Protein in human respiratory syncytial virus that 12 drugs act on.

  • Drugs that act on it: 12
  • Approved: 4
  • In phases 1 to 3: 8
  • Sponsors: 8

Who is on it, and how far along

Every drug ChEMBL records acting on F, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3
  • Antibody 4
  • Other 5

Approved4

Phase 34

  • Clesrovimab
  • Ziresovir
  • Motavizumab
  • Rilematovir

Phase 22

  • ALX-0171
  • Sisunatovir

Phase 12

  • MEDI-557
  • MEDI-564

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • MedImmune LLC217%
  • Shanghai Ark Biopharmaceutical Co., Ltd.18%

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 10 of 12 act as: Fusion glycoprotein F0 inhibitor; the rest name their own mechanism.
NirsevimabApprovedAstraZeneca PharmaceuticalsAntibodyInhibitor18
PalivizumabApprovedSobiAntibodyInhibitor1
Respiratory syncytial virus pre-fusion glycoprotein fApproved—Vaccine componentVaccine antigenFusion glycoprotein F0 vaccine antigen0
Respiratory syncytial virus pre-fusion glycoprotein f mRNAApproved—Vaccine componentVaccine antigenFusion glycoprotein F0 vaccine antigen0
ClesrovimabPhase 3Merck & Co. (MSD)AntibodyInhibitor3
ZiresovirPhase 3Shanghai Ark Biopharmaceutical Co., Ltd.Small moleculeInhibitor1
MotavizumabPhase 3MedImmune LLCAntibodyInhibitor0
RilematovirPhase 3Johnson & JohnsonSmall moleculeInhibitor0
ALX-0171Phase 2SanofiOtherInhibitor0
SisunatovirPhase 2PfizerSmall moleculeInhibitor0
MEDI-557Phase 1MedImmune LLCOtherInhibitor0
MEDI-564Phase 1—OtherInhibitor0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 12 in all, from ClinicalTrials.gov.
Impact of Clesrovimab on Respiratory Pathogen Shedding in Infants: The RSV-SHIELD TrialClesrovimabPhase 4Not yet recruitingUniversity of CreteNov 20, 2026
Severe Pediatric Respiratory Syncytial Virus Infections Occurring in the Era of Antiviral ProphylaxisClesrovimab, Nirsevimab—Not yet recruitingAssistance Publique - Hôpitaux de ParisOct 26, 2026
The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration EvaluationClesrovimabPhase 4Not yet recruitingEmory UniversitySep 17, 2026
ENVIEANCILLAIRE: Efficacy of Nirsevimab in Children Hospitalised With RSV Bronchiolitis - A Subsidiary Study on the Immune Signature and Microbial EnvironmentNirsevimab—RecruitingCentre Hospitalier Intercommunal CreteilJul 13, 2026
A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.ZiresovirPhase 2 / Phase 3RecruitingShanghai Ark Biopharmaceutical Co., Ltd.Jun 22, 2026
THRIVE - Trial of Passive Humoral RSV Immunity for Value and EffectivenessNirsevimabPhase 4RecruitingMenzies School of Health ResearchMay 11, 2026
Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term InfantsNirsevimabPhase 1 / Phase 2Not yet recruitingShanghai Institute Of Biological ProductsJan 23, 2026
The Effectiveness of Early Immunisation With Nirsevimab on Preschool Wheezing in France, Based on an Analysis of Data From the French Health System Database.Nirsevimab—Not yet recruitingHospices Civils de LyonJan 5, 2026
Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in BogotáNirsevimab—Active, not recruitingBogotá District Health SecretariatDec 12, 2025
Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV VaccinationNirsevimabPhase 3RecruitingCentre Hospitalier Annecy GenevoisNov 18, 2025
A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of KoreaNirsevimab—RecruitingSanofiOct 1, 2025
Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) DiseasePalivizumabNot applicableActive, not recruitingAstraZenecaFeb 28, 2025

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364165, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.